micro<scp>RNA</scp> Detection in Blood, Urine, Semen, and Saliva Stains After Compromising Treatments

Layne, Tiffany; Green, Raquel A; Lewis, Carolyn; Nogales, Francy; Cruz, Tracey C Dawson; Zehner, Zendra E.; Seashols‐Williams, Sarah

doi:10.1111/1556-4029.14113

Cited by 30 publications

(23 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Circulating miRNAs are promising biomarkers, highly stable at extreme conditions of pH, chemical treatments and temperature. Moreover, circulating miRNAs are preserved from RNAse activity because they are carried by RNA-binding proteins in extracellular vesicles and lipoprotein [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

MicroRNAs in Hypertrophic, Arrhythmogenic and Dilated Cardiomyopathy

et al. 2021

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a class of non-coding RNAs of about 20 nucleotides in length, involved in the regulation of many biochemical pathways in the human body. The level of miRNAs in tissues and circulation can be deregulated because of altered pathophysiological mechanisms; thus, they can be employed as biomarkers for different pathological conditions, such as cardiac diseases. This review summarizes published findings of these molecular biomarkers in the three most common structural cardiomyopathies: human dilated, arrhythmogenic and hypertrophic cardiomyopathy.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNAs in Hypertrophic, Arrhythmogenic and Dilated Cardiomyopathy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Recently, microRNAs (miRNAs) are gaining increasing attention in the field of neuropsychiatric diseases, given the important regulatory roles of miRNAs in cell growth, neural differentiation, and synaptic plasticity. 19 Additionally, miRNAs are suitable for biomarkers because they are abundant in various body fluids (such as blood, saliva, and urine), 5 and these body fluids can be collected easily and non-invasively. In fact, a number of studies have shown blood miRNA aberrations in patients with MMD when compared with healthy control (HC) subjects, and several blood miRNAs have been proposed as potential biomarkers for the diagnosis of MDD.…”

Section: Introductionmentioning

confidence: 99%

<p>Serum Exosome-Derived miR-139-5p as a Potential Biomarker for Major Depressive Disorder</p>

Liang

Liao

et al. 2020

NDT

View full text Add to dashboard Cite

Background MicroRNAs (miRs) have been suggested to be biomarkers to inform the diagnosis of major depressive disorder (MDD). We have previously shown that exosome-derived miR-139-5p had potential in differentiating between patients with MDD and healthy control (HC) subjects. Materials and Methods To validate the potential of exosome-derived miR-139-5p as a biomarker for MDD, here we recruited 30 patients with MDD and 30 HC subjects, and used TaqMan probes to detect serum exosomal miR-139-5p levels. Results The data showed that patients with MDD had significantly increased exosomal miR-139-5p levels when compared with controls. Correlation analysis suggested that sex, age, and body mass index did not significantly affect blood exosomal miR-139-5p levels in the tested subjects. The ROC curve showed that serum-derived miR-139-5p had reasonable performance in discriminating patients with MDD and HC subjects, with a sensitivity of 0.867 and specificity of 0.767, and the AUC was 0.807. Discussion Taken together, these results demonstrated that patients with MDD were accompanied by significantly increased blood exosomal miR-139-5p levels, and exosomal miR-139-5p is a promising biomarker for the diagnosis of MDD.

show abstract

“…The application of circulating RNA molecules, including non-coding RNAs (ncRNAs), as biomarkers has been widely explored in the last few decades; miRNAs have been suggested as diagnostic biomarkers for several diseases, including neurodegenerative [ 8 , 9 ], neurodevelopmental [ 10 ], traumatic [ 11 ], neoplastic [ 12 , 13 ], and metabolic conditions [ 14 , 15 ]. Indeed, miRNAs have been detected in all analyzed biological fluids [ 16 , 17 , 18 ], making them useful as disease biomarkers measurable in all body districts. Similarly, long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), a recently discovered class of ncRNAs, are emerging as new potential disease biomarkers, also in AD [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Uncharacterized RNAs in Plasma of Alzheimer’s Patients Are Associated with Cognitive Impairment and Show a Potential Diagnostic Power

Barbagallo

Martino

Grasso

et al. 2020

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) diagnosis is actually based on clinical evaluation and brain-imaging tests, and it can often be confirmed only post-mortem. Therefore, new non-invasive molecular biomarkers are necessary to improve AD diagnosis. As circulating microRNA biomarkers have been proposed for many diseases, including AD, we aimed to identify new diagnostic non-small RNAs in AD. Whole transcriptome analysis was performed on plasma samples of five AD and five unaffected individuals (CTRL) using the Clariom D Pico Assay, followed by validation in real-time PCR on 37 AD patients and 37 CTRL. Six differentially expressed (DE) transcripts were identified: GS1-304P7.3 (upregulated), NONHSAT090268, TC0100011037, TC0400008478, TC1400008125, and UBE2V1 (downregulated). Peripheral blood mononuclear cells (PBMCs) may influence the expression of circulating RNAs and their analysis has been proposed to improve AD clinical management. Accordingly, DE transcript expression was also evaluated in PBMCs, showing no difference between AD and CTRL. ROC (receiver operating characteristic) curve analysis was performed to evaluate the diagnostic accuracy of each DE transcript and a signature including all of them. A correlation between cognitive impairment and GS1-304P7.3, NONHSAT090268, TC0100011037, and TC0400008478 was detected, suggesting a potential association between their extracellular abundance and AD clinical phenotype. Finally, this study identified six transcripts showing altered expression in the plasma of AD patients. Given the need for new, accurate blood biomarkers for AD diagnosis, these transcripts may be considered for further analyses in larger cohorts, also in combination with other biomarkers, aiming to identify specific RNA-based biomarkers to be eventually applied to clinical practice.

show abstract

microRNA Detection in Blood, Urine, Semen, and Saliva Stains After Compromising Treatments

Cited by 30 publications

References 45 publications

MicroRNAs in Hypertrophic, Arrhythmogenic and Dilated Cardiomyopathy

MicroRNAs in Hypertrophic, Arrhythmogenic and Dilated Cardiomyopathy

<p>Serum Exosome-Derived miR-139-5p as a Potential Biomarker for Major Depressive Disorder</p>

Uncharacterized RNAs in Plasma of Alzheimer’s Patients Are Associated with Cognitive Impairment and Show a Potential Diagnostic Power

Contact Info

Product

Resources

About